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Yp¼0.98), cardiac death (96.8% vs 97.1%, p¼0.84), MI (91.9% vs 89.4%, p¼0.40), Q-
wave MI (100.0% vs 98.6%, p¼1.0), non-Q-wave MI (91.9% vs 90.8%, p¼0.70), and
TVR (94.1% vs 94.2%, p¼0.98).
CONCLUSION Using the OAS as a lesion preparation tool prior to stent deployment in
both diabetics and non-diabetics may offer patients with severely calciﬁed coronary
lesions a new treatment option, with low rates of MACE at one-year post-procedure.
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BACKGROUND History of prior coronary artery bypass grafting (CABG) may be asso-
ciated with increased incidence of major adverse cardiac events (MACE) in patients
undergoing repeat CABG, percutaneous coronary intervention, or medical treatment.
In this analysis, one year safety outcomes were evaluated in patients with and
without history of CABG treated with orbital atherectomy for de novo, severely
calciﬁed coronary lesions.
METHODS ORBIT II, a prospective, multicenter, non-blinded trial, enrolled 443 pa-
tients with severely calciﬁed coronary lesions. Orbital atherectomy was used to
modify lesions for stent placement. One year safety outcomes were compared in
patients with and without history of CABG (N¼65 and N¼378).
RESULTS ORBIT II patients with history of CABG were more likely to be male and have
a higher prevalence of diabetes, history of dyslipidemia, hypertension, and myocar-
dial infarction (MI). One year safety outcomes are presented in Table I. The higher rate
of in-hospital MACE (16.9% vs. 8.5%, p¼0.04) in the prior CABG group was likely
driven by the higher rate of non-Q-wave MI (15.4% vs. 7.5%, p¼0.05). At one year,
however, using multivariate analysis prior CABG was not associated with increased
MACE (HR 0.57, p¼0.08) after adjusting for baseline and pre-procedural factors.
CONCLUSION Preparation of severely calciﬁed coronary lesions with orbital athe-
rectomy facilitated stent delivery in patients with a history of CABG, resulting in low
rates of 1-year MACE, MI, cardiac death, and target vessel revascularization.
Table I. ORBIT II Safety Outcomes Through 1-Year Follow-upPrior CABG No Prior CABG p-value1-yearMACE (%) 26.3 14.7 0.02Cardiac death (%) 4.7 2.7 0.41Q-wave MI (%) 1.5 0.8 0.57Non-Q-wave MI (CK-MB>3XULN) (%) 15.4 7.7 0.05TVR (%) 8.0 5.5 0.45CRT-131
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BACKGROUND Little information is available regarding the comparison between the
ﬁrst- and second-generation drug-eluting stents (DES) following rotational athere-
cotmy (ROTA) for patients with heavily calciﬁed coronary lesions (HCCL).
METHODS Ninety-nine patients with HCCL who underwent RA prior to ﬁrst-genera-
tion DES (n¼40, 53 lesions) or second-generation DES (n¼59, 63 lesions) implantation
were retrospectively analyzed. The primary endpoint was the rate of major adverse
cardiac events (MACE).
RESULTS Baseline clinical and procedural characteristics were similar between the
two groups, except for more complex type C lesions (81.0% vs. 58.8%, p¼0.01) and
more proportion of post dilation (52.4% vs. 23.1%, p¼0.001) in the second-generation
DES group. The procedure success rate was similar in the two groups (95% vs. 100%,
p¼0.161). Compared with ﬁrst-generation DES group, there were no differences
regarding the occurrence of MACE (11.9% vs. 12.8%, p¼1.000), TLR (3.6% vs. 2.7%,
p¼1.000) and all-cause death (8.5% vs. 10.3%, p¼1.000) in the second-generation DES
group at 1-year follow-up. No stent thrombosis was found in all patients.
CONCLUSIONS The ﬁrst- and second-generation DES following ROTA resulted in
comparable outcomes in patients with HCCL at 1 year follow-up.Table I. In-hospital, 6-month and 1-year clinical outcomesVariable1-st generation DES
(n[40, 53 lesions)2-nd generation DES
(n[59, 63 lesions) p- valueIn-hospital MACE (%) 5.0 0 0.1616 month follow-up (%)MACE 7.5 6.8 1.000All cause death 5.0 5.1 1.000Cardiac death 0 5.1 0.274Q-wave MI 0 0 _TLR 2.5 1.7 1.000Stent thrombosis 0 0 _1 year follow-up (%)MACE 12.8 11.9 1.000All cause death 10.3 8.5 1.000Cardiac death 0 8.5 0.153Q-wave MI 0 0 _TLR 2.7 3.6 1.000Stent thrombosis 0 0 _MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularizationCRT-132
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BACKGROUND This study aimed to compare the outcome following plain old balloon
angioplasty (POBA), cutting balloon angioplasty (CBA) and rotational atherectomy
(ROTA) in patients with heavily calciﬁed coronary lesions (HCCL).
METHODS Clinical data of the patients with HCCL who underwent POBA (n¼220),
CBA (n¼253), or ROTA (n¼264) prior to DES implantation from 2003-2013 were
retrospectively analyzed. The occurrence of major adverse cardiac events (MACE),
deﬁned as all-cause death, myocardial infarction (MI) or target lesion revasculariza-
tion (TLR) were compared at one year follow-up.
RESULTS Baseline clinical characteristics were similar among the three groups,
except for older patients age, and type C lesions in the ROTA versus the CBA and
POBA (71.910.4 vs. 68.010.8, 68.711.8 years, p<0.001), and (61.7% vs. 35.8%,
45.0%, p<0.001) respectively. Angiographic success was achieved in all patients. At
one year follow-up, the MACE rate was similar (14.6% in the ROTA group, 12.3% in the
POBA group and 8.3% in the CBA group, p¼0.204). The occurrence of stent throm-
bosis was 0.6% in the CBA and 0% in the ROTA and POBA group.
CONCLUSIONS In patients with HCCL, ROTA was frequently used for the treatment of
more complex lesions compared with CBA and POBA. The different strategies with
ROTA, CBA and POBA prior to DES implantation resulted in the similar long-term
outcomes after optimal lesion preparation for patients with HCCL.Table I. 6-month and 1-year clinical outcomesVariable POBA (n[220) CBA (n[253) ROTA (n[264) p value6 month follow-up (%)MACE 9.2 3.9 8.6 0.118All cause death 6.2 2.2 6.3 0.135Cardiac death 1.6 1.1 1.8 0.897Q-wave MI 0 0 0 -TLR 2.4 2.3 2.4 1.00Stent thrombosis 0 0.5 0 1.001 year follow-up (%)MACE 12.3 8.3 14.6 0.204All cause death 8.2 4.5 9.8 0.178Cardiac death 2.5 1.3 3.1 0.611Q-wave MI 0 0.7 0 1.00TLR 3.5 3.9 5.2 0.765Stent thrombosis 0 0.6 0 0.629MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularization
